Become a Member of the U.S. Alliance of Diabetes Treatment Centers Today!

Welcome to the
U.S. Alliance of Diabetes Treatment Centers


Our Mission Statement

The U.S. Alliance of Diabetes Treatment Centers (USADTC) is a multi-disciplinary medical professional membership alliance. We are committed to transparency and the highest ethical standards of care. We are a scientific and educational organization dedicated to promoting the science of clinical diabetes and metabolism for the improvement of patient care and public health. 

About Us


The U.S. Alliance of Diabetes Treatment Centers is gaining momentum. 

We are raising funds to sponsor clinical trials on Diabetes Metabolic Restorative Therapy (DMRT) and are currently screening potential volunteers for eligibility according to strict protocols.

DMRT is a metabolic pancreas treatment that has shown promising and life-changing results for many Type 1 and Type 2  diabetes patients but remains to be fraught with skepticism and still considered an experimental treatment by many in the medical arena.

Our research will meet the rigorous standards and criteria within the medical and scientific community before being published and we will strive to bring the world definitive protocols and guidelines that will be able to assist providers with well-defined health care decisions.


The U.S. Alliance is lobbying on Capitol Hill, educating our current legislators, insurance payers and multi-specialty providers in the healthcare community with systematically developed, evidence-based research that Diabetes Metabolic Restorative Therapy (DMRT) has the ability to slow, stop or reverse the progression of comorbidities in many diabetic patients.  

We are engaging with governmental agencies to  identify the gaps in diabetes care and increase state and federal support to expand DMRT access, treatment and insurance coverage for people suffering from the complications of diabetes.

Science and technology drive health care, with technology increasing the pace of scientific discovery. Innovations in therapies and care models can expand access to care and remove disparities.

 We believe that providers and patients can actively influence healthcare policy.

Our already heavily burdened healthcare system as well as our communities will greatly benefit. 


We support and advocate for people with diabetes and their loved ones who deserve better treatment options and care by providing new treatment strategies. 

We strive to help diabetic patients improve their quality of life, achieve their wellness goals, and heal their body to live their best life possible.  


Updates from The Hill

U.S. Alliance Washington D.C. Updates

Wednesday and Thursday, July 18-19, 2018

Washington D.C.

We held a very successful Alliance summit in Washington DC with Congress members and Felipe Miranda of Miami, FL, Jim Novak of San Diego, CA, Lon Von Hurwitz of South Bronx, NY, and Tyrone Lam representing First Americans Health and Scott Dacey from PACE Government Affairs. Jim Walker of Memphis, TN contributed to the planning of this summit based on our previous Hill visits, but was unable to make it. 

We had an opening Alliance dinner at the Capitol Hill Club Tuesday evening July 17, thanks to Scott  Dacey, to focus our messaging for our upcoming meetings regarding CMS reimbursement, planned clinical trials research, and the potentials for coverage with evidence development and/or a grant from the CMMI (CMS Innovation Center) during the research process to expand the numbers of patients to be included. We also visited at the Club with Florida Congressman Mario Diaz Balard (R-FL), a member of the important Appropriations Committee.  

On Wednesday we first had breakfast with Diabetes Caucus Co-Chair Tom Reed (R-NY) and with AMA SVP for Advocacy, Rich Deem, to  discuss the value of the therapy and our issues with CMS. This was our  second meeting with Congressman Reed, and he has been very supportive. Mr. Deem informed me later he was fascinated with the therapy and wants to know more about it, and to perhaps help with our efforts with CMS when we are ready.

We then had a positive meeting with Congressman Raul Ruiz MD (D-CA),  an important member of the Health Subcommittee of House Energy and Commerce. We were also fortunate to visit with the office of Congressman Devin Nunes (R-CA), an influential member of House Ways and Means. Both Nunes and his staff expressed a willingness to learn more about our progress as we move forward.   It should be noted that both members can help enlist their colleagues who serve on their two powerful committees, both of which have jurisdiction over CMS and its authorized activities. 

We also had a fortuitous unscheduled visit with Greg Walden (R-OR), who is the powerful Chair of Energy and Commerce, and with whom Scott Dacey and I have worked in the past. 

During the afternoon we first met with the staff of Congressman Scott Peters (D-CA) (Jim Novak is a constituent). We then had a short but excellent meeting with the other Diabetes Caucus Co-Chair, Congresswoman Diana Degette (D-CO) who was extremely interested in the therapy and our issues with CMS.  She then asked her staff to spend time with us and to report back as to how she and the Caucus can be helpful in the future. 

Finally we met members of the senior leadership team of the National Congress of American Indians,  including individuals who have previously held senior leadership  positions at the Indian Health Service.  During this meeting we gained significant insight as to how to successfully work  with interested tribes who want to be engaged in research and in making the treatment available as well.  Amazingly, several individuals who are now senior leaders of the IHS are those with whom I served as a Commissioned Officer early in my career. 

The final meeting on Thursday was with the office of Congressman Markwayne Mullin (R-OK), which Scott Dacey and Tyrone Lam conducted since the rest of us were unable to stay through Thursday. Congressman Mullin is also a member of the House Energy and Commerce Committee and one of two Native Americans serving in the United States House of  Representatives. 

Meeting with so many actual members of Congress was very unusual and important. While repeat  meetings will be needed to strengthen our message and relationships with these and other members we want to educate, this investment will be very valuable when we have enough efficacy data to present to CMS as the research proceeds. 

I would like to offer a special thanks to Scott Dacey, whose firm represents many Indian nations, for the excellent help organizing meetings and for the Capitol Hill Club dinner event. 

We hope all Alliance members can participate when we plan the next Hill visit. 

Best regards, Jack

Tuesday, June 12, 2018

Washington D.C.  

U.S. Alliance of Diabetes Treatment Centers Chairman of the Board, Jack Lewin MD and Tennessee Board Member Jim Walker held several important meetings in Washington DC this week ON BEHALF OF THE U.S. ALLIANCE OF DIABETES TREATMENT CENTERS seeking Congressional support for continuation of or resumption of CMS/Medicare reimbursement for Diabetes Metabolic Restorative Therapy (DMRT). We were accompanied in our meetings by Bill Signer of the Carmen Group.

We had lunch with Congressman Tom Reed R-NY, who is Co-Chair of the Congressional Diabetes Caucus. Reed has personally struggled with Type 2 diabetes, and has a son with Type 1. He understands the issues well and has expressed a interest in supporting our efforts. We believe he will prove to be a strong advocate.

We met for the second time with the staff leaders of the Health Education Labor and Pensions (HELP) Committee chaired by Senator Lamar Alexander R-TN, who has also pledged to advocate for us. Jim Walker knows him personally. They feel a much more effective approach than writing letters on our behalf to CMS is to arrange a direct meeting of the Alliance with Seema Verma, Administrator of CMS, to request coverage with evidence development (CED) or a CMS Innovation Center (CMMI) pilot project grant.  Both would provide reimbursement during a typical 12 month period while research and or outcomes data is collected and shared with the agency.

We also met with senior staff of Congresswoman Marsha Blackburn R-TN, who organized the meeting after discussing our goals directly with Jim Walker, her friend and constituent. They offered to get others engaged and will support Senator Alexander’s effort to get a top level CMS meeting going.

I met briefly later on Wednesday with staff of two other members of the House I know personally to let them know what we’re doing. When the Seema Verma meeting is scheduled, Alliance members who can attend will also want to meet with their own state members of Congress at the same time.

We made some great progress on this visit, but there is more to come!  — Jack Lewin MD


Research Updates

 Diabetic Macular Edema (DME) and Diabetic Retinopathy Reversal (DRE)

DME is an accumulation of fluid in the macula—part of the retina that controls our most detailed vision abilities—due to leaking blood vessels. 

Evaluation of existing data with DMRT indicates that DME responds quickly.

DRE affects blood vessels in the light-sensitive tissue called the retina. It is the most common cause of vision loss among people with diabetes and the leading cause of vision impairment and blindness among working-age adults.

Hypothesis: DMRT will arrest the progression of these disorders and, to some degree, reverse their impact.

Methodology: Study group will receive standardized DMRT in addition to conventional therapy.

Principal Investigators:

 Neil S. Patel, MD - NYC

Jack lewin, MD - NYC


Study Size: 40 Patients + 30 Patient Control Group

Study Time Frame: 6 months with interim report in 3 months

Study Location(s): 

New York City, New York

Endpoints: Retinavues and standard ophthalmological metrics will demonstrate  quantifiable improvement in DME and DRE. amputations.pdf

Past Events

Thursday, July 19, 2018  

 9:15 AM

Taylor Hittle, Office of Congressman Markwayne Mullin (R-OK), Member of the House Energy and Commerce Committee


Wednesday, July 18 

8:00 AM

Fundraiser for Congressman Tom Reed (R-NY)

9:45 AM

Dr. Raul Ruiz (D-CA) Member of the Health Subcommittee of the House Energy and Commerce Committee

12:00 PM

Max Kannen Office of Congressman Devin Nunes (R-CA) Member of the Health Subcommittee on Ways and Means

2:00 PM

Congressman Scott Peters (D-CA)

Member of the House Energy and Commerce Committee

3:30 PM

Shahil Chaudhary, Office of Congresswoman Diana Degette (D-CO) Member of the Health Subcommittee of the House, Energy and Commerce Committee

4:30 PM

Dr. Yvette Roubideaux, Director, Policy Research Center, National Congress of American Indians


Tuesday, June 12, 2018 

 8:30 AM EST 

Congressman Richard Neal (D-MA) Breakfast

Mr. Neal is the ranking democrat on ways and Means and would become Chairman if the Democrats take over W&M has oversight for CMS Budgets.

12:00 PM EST

Congressman Tom Reed (R-NY) Lunch

Mr. Reed is a very influential member of the House Committee on Ways & Means and is a member of the Republican Whip team. He is also the Co-Chairman of the Congressional Diabetes Caucus.


National Diabetes Statistics Report, 2017 |

Estimates of Diabetes and Its Burden in the United States 


Prevalence of Both Diagnosed and Undiagnosed Diabetes 

• An estimated 30.3 million people of all ages—or 9.4% of the U.S. population—had diabetes in 2015 (Methods).
• This total included 30.2 million adults aged 18 years or older (12.2% of all U.S. adults), of which 7.2 million (23.8%) 

were not aware of or did not report having diabetes (Table 1) (Methods).
• The percentage of adults with diabetes increased with age, reaching a high of 25.2% among those aged 65 years 

or older (Table 1). 

• Comparedtonon-Hispanicwhites,theage-adjustedprevalenceofdiagnosedandundiagnoseddiabeteswas higher among Asians, non-Hispanic blacks, and Hispanics during 2011–2014

Science Magazine 

by Science News Staff | March 23, 2018

President Donald Trump today signed into law a $1.3 trillion spending package that largely rejects deep cuts to research agencies proposed by the White House and, in many cases, provides substantial increases.Here’s a look at some of the top line numbers for key science agencies:

  • The National Institutes of Health (NIH) in Bethesda, Maryland, receives a $3 billion, 8.3% increase to $37 billion. That is well above the increase proposed by either the House of Representatives or the Senate in their versions of the spending bills, and a blunt rejection of the 22% cut proposed by the White House. Included is an additional $414 million for Alzheimer’s disease research, for a total of $1.8 billion, and a $27 million boost, to $543 million, for clinical and translational science funding. The NIH increase is “beyond words, folks,” tweeted Benjamin Corb, director of public affairs at the American Society for Biochemistry and Molecular Biology in Rockville, Maryland.
  • The National Science Foundation in Alexandria, Virginia, would get $7.8 billion, a 3.9% or $295 million increase. 
  • The Department of Energy’s Office of Science in Washington, D.C., would receive $6.26 billion, an $868 million increase. That is roughly a 15% increase, rather than the 15% cut the White House proposed. 
  • A $457 million, 7.9% increase for NASA science programs, to $6.2 billion. The bill increases the agency’s planetary science program by some 21%, or $382 million, to $2.2 billion. Overall, NASA gets $20.7 billion, $1.1 billion above 2017.
  • Spending at the National Oceanic and Atmospheric Administration in Silver Spring, Maryland, would grow by $234 million, to $5.9 billion overall. 
  • The National Institute of Standards and Technology ​in Gaithersburg, Maryland, would get $1.2 billion, $247 million above 2017 levels.
  • The U.S. Geological Survey in Reston, Virginia, gets $1.1 billion, $63 million above 2017 levels. The bill preserves the agency’s eight climate science centers.
  • Research programs at the U.S. Department of Agriculture in Washington, D.C., would grow by $33 million, to $1.2 billion.
  • The budget of the Environmental Protection Agency ​in Washington, D.C., remains flat at $8.1 billion.

Our Members

Our Members are multi-disciplinary physicians, healthcare administrators and healthcare business owners. They may also be nurse practitioners, registered nurses and healthcare practice managers. 

All of our members are engaged and have a continuing professional interest in the research outcomes of Diabetes Metabolic Restorative Therapy (DMRT) in conjunction with utilizing conventional diabetes treatment, including medication management, nutrition and education for their diabetic patients. 

Our Members are committed to the mission, supporting the purposes and objectives of the U.S. Alliance of Diabetes Treatment Centers and contributing their experience, insights and time.

It is the personal responsibility for all of our Members to be held up to the highest degree of professional ethics and personal integrity. 

Benefits of Being a Member

Your membership gives you access to networking opportunities with multi-specialty providers and other Diabetes Metabolic Restorative Therapy (DMRT) providers.

Your membership grants you inclusion and information with regards to:

· Legislative strategies of the Alliance

· Registry concept

· Protocol consistency and effectiveness collaboration

· Research update and progress reports

· USADTC Association business meetings and agendas

· Strategic Plans re: CMS and research objectives

Full Charter membership status confers the privilege of nominating board members, voting and holding a board seat. These memberships are not transferable. 

  Full Charter Members contribute financially by paying annual membership dues.

The Associate Membership is a basic membership requiring no financial dues.

Associate members do not have the privilege of nominating board members, voting or holding a board seat.

How to Become a Member

Send an email request to the Chairman of the Board of the US Alliance of Diabetes Treatment Centers at Jack Lewin M.D.,

Send us a brief bio and reason why you would like to become a member. 

Qualifications will be reviewed and the Board will vote on acceptance. 

If you desire to become a Full Charter Member, your membership dues must be paid for full membership privileges.

If you desire to become an Associate Member no membership dues but in-kind services and collaboration (e.g. Best Practices, Protocol sharing, etc.) will be required.

U.S. Alliance Upcoming Events

Eastern Standard Times

No upcoming events.

Upcoming Research


Neuropathy Feet

Neuropathy Hands

More to Come

Contact Us

Please contact us directly with any questions, comments, or inquiries you may have.

U.S. Alliance of Diabetes Treatment Centers

2825 3rd Avenue, Bronx, New York, New York 10455, United States

(202) 262-6601


Monday - Friday: 9AM–5PM EST